Supernus Pharmaceuticals, Inc.
SUPN
$50.81
$0.280.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.14% | 90.90% | -300.53% | 290.23% | -177.16% |
| Total Depreciation and Amortization | 4.46% | 0.85% | 16.14% | 4.78% | 8.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.39% | 541.10% | 146.30% | -60.85% | -47.03% |
| Change in Net Operating Assets | 142.36% | -4.38% | -528.12% | -17.36% | 371.12% |
| Cash from Operations | 234.95% | 132.21% | -205.35% | 91.30% | -31.09% |
| Capital Expenditure | -- | -231.01% | 71.65% | -39.14% | -53.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 62.23% | -114.88% | 1,234.01% | -180.10% | 402.97% |
| Cash from Investing | 62.55% | -205.35% | 259.13% | -182.02% | 395.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 59.75% | -63.96% | 624.69% | 60.43% | -70.31% |
| Repurchase of Common Stock | -14,593.55% | 96.18% | -1,663.04% | 98.62% | -238.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 18.87% | 88.58% | -- |
| Cash from Financing | 6.91% | -59.53% | 2,153.26% | 104.37% | -463.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 346.13% | -382.65% | -71.90% | -37.95% | 23.52% |